Medical ETF Guotai (159828) rises over 1.2%, China’s original research nuclear medicine new drug achieves a major breakthrough

Ask AI · How China’s homegrown radiopharmaceutical breakthrough could lift the Medical ETF?

On April 8, the Cathay Medical ETF (159828) rose by more than 1.2%, and a major breakthrough has been achieved for a new China-developed homegrown radiopharmaceutical drug.

Ping An Securities said that China’s homegrown radiopharmaceutical new drug has brought a major breakthrough: Radeo’s Category 1 radiopharmaceutical innovative drug has been approved for marketing. At the industry level, in the CXO and upstream sectors, medical financing saw a modest increase; factors such as BD deals and a rebound in H-share IPOs have reignited enthusiasm for innovation. On the order side, there has been a rebound. In the life sciences upstream, the core development logic of “expanding overseas + penetrating the domestic market” continues to be carried out. In medical devices, in the short term the domestic market faces some pressure due to policy impacts, but with the continued rollout of anti-“involution” policies, most segments completing centralized procurement (i.e., clearing out), and companies continuing to pursue innovation upgrades and expand international business, the industry fundamentals are expected to improve. From the innovation main theme, you may want to focus on technology platform directions such as the metabolism field (e.g., weight loss), the chronic disease field, the central nervous system field, as well as small nucleic acid drugs, radiopharmaceuticals (RDC), and CART therapy.

The Cathay Medical ETF (159828) tracks the CSI Medical Index (399989). The index selects securities of listed companies in areas including medical devices, medical services, and healthcare informatization from the A-share market as index constituents, to reflect the overall performance of securities of listed companies related to the medical theme. The index has relatively strong growth characteristics and a high level of industry concentration, and overall it leans toward the large-cap growth style.

Risk warning: Mentioned individual stocks are only used for industry event analysis and do not constitute any recommendation or investment advice regarding any individual stock. Short-term index gains or losses are for reference only and do not represent the index’s future performance, nor do they constitute any commitment or guarantee regarding fund performance. Views may be adjusted as market conditions change and do not constitute investment advice or commitments. The fund risk-and-return characteristics mentioned for each product differ; investors are kindly requested to carefully read the fund legal documents, fully understand product features, risk ratings, and the principles of profit distribution, choose products that match their own risk tolerance, and invest cautiously. For information about fund fees, please refer to the legal documents.

Economic Daily News